Latanoprost Stallpharma (Latanoprost)

Latanoprost activates prostaglandin F‑type receptors in the eye, which increases the uveoscleral outflow of aqueous humor. By enhancing this drainage pathway, the drug reduces intra‑ocular pressure, the primary risk factor in glaucoma progression.

The dosing regimen is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the clinician’s instructions.

Limited clinical data are available for use in pregnancy or lactation. Because animal studies have shown potential risks, the medication should only be used if the potential benefit justifies the possible risk to the fetus or infant, and under close medical supervision.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with beta‑blocker eye drops such as timolol, latanoprost generally provides a greater reduction in intra‑ocular pressure with once‑daily dosing and a different side‑effect profile. Beta‑blockers may cause systemic cardiovascular effects, whereas latanoprost’s most common adverse events are ocular, such as iris pigmentation changes.

Store the ophthalmic solution at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light, and avoid exposure to moisture. Do not freeze the product.

The medication is applied as a single drop into the conjunctival sac of the affected eye(s) in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and close the eyelid gently after instillation.

Serious adverse events include severe eye inflammation (uveitis or iritis), allergic reactions such as swelling or difficulty breathing, sudden vision loss, and ocular infections. Any of these symptoms require immediate medical evaluation.

Patients with known hypersensitivity to latanoprost or any component of the formulation should avoid the product. It is also contraindicated in eyes with active inflammation, infection, or recent ocular surgery until cleared by an eye specialist.